Skip to main content

Table 1 Patient characteristics

From: Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound

  Group T (n = 8) Group L (n = 6) p value
Age (years) 61.5 ± 13.7 63.5 ± 11.5 0.7813
Men 5 (62.5 %) 3 (50.0 %) 0.1477
Body surface area (m2) 1.64 ± 0.11 1.60 ± 0.10 0.5998
NYHA class III or IV (n, %) 4 (50 %) 1 (16.7 %) 0.1977
Preoperative laboratory examinations
 Hb (g/dL) 10.9 ± 1.8 10.4 ± 1.1 0.5397
 Na (mEq/L) 139.1 ± 4.0 136.0 ± 3.6 0.1567
 Cre (mg/dL) 1.20 ± 0.54 1.02 ± 0.28 0.478
 T-Bil (mg/dL) 1.4 ± 0.6 1.02 ± 0.2 0.408
 TP (g/dL) 6.2 ± 0.5 6.3 ± 0.2 0.792
 Alb (g/dL) 3.5 ± 0.3 3.5 ± 0.2 0.831
 eGFR (ml/min./1.73 m2) 47.6 ± 26.6 52.9 ± 14.4 0.668
 CKD stage 3b or worse (n, %) 4 (50 %) 2 (33.3 %) 0.533
Preoperative echocardiography
 LVEDD (mm) 56.8 ± 19.8 50.3 ± 9.4 0.371
 LVEF (%) 43.1 ± 14.0 52.0 ± 6.7 0.180
 TAPSE (mm) 16.0 ± 5.0 20.3 ± 3.1 0.086
 RVFAC (%) 33.5 ± 7.1 38.3 ± 6.5 0.214
Euroscore 12.6 ± 8.1 8.0 ± 4.0 0.2486
Japan Score 15.9 ± 11.8 10.1 ± 5.1 0.2820
Type of surgery (p value based on CABG alone vs. others)    0.0499
 CABG alone 0 (0 %) 2 (33.3 %)  
 Valvular surgery alone 5 (62.5 %) 3 (50.0 %)  
 CABG + Valvular surgery 1 (12.5 %) 1 (16.7 %)  
 Pericardiectomy 1 (12.5 %) 0 (16.7 %)  
 Pulmonary thrombectomy 1 (12.5 %) 0 (16.7 %)  
  1. Abbreviations not defined in the text; NYHA New York Heart Association, Hb hemoglobin, Na sodium; Cre creatinine, T-Bil total bilirubin, TP total protein, Alb albumin, eGFR estimated glomerular filtration rate, CKD chronic kidney disease, LVEDD left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, TAPSE tricuspid annual plane systolic excursion, RVFAC right ventricular fractional area change, CABG coronary artery bypass grafting